Sanofi India Limited

Sanofi India Limited (SANOFI) is a small-cap Healthcare company valued at ₹6,776 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Sanofi India Limited last traded at ₹2,942.1, modestly down 0.51% on the day.

Recent developments

2026-08-10: Sanofi India reported a 19% rise in profit before tax to ₹112 crore in Q2 2026, driven by strong performance in diabetes treatments. 2026-08-04: The company's Q2 2026 profit grew 19% due to strong diabetes performance. 2026-09-30: Sanofi India's dividend income is at risk as it declared a lower dividend of ₹123 per share in FY26 compared to ₹167 in FY24.

Financial performance

The company's annual revenue fell 8.7% to ₹1,837 crore, while annual net profit dropped 21.1% to ₹327 crore. In the latest quarter, revenue rose 7.8% to ₹438 crore, and net profit increased 19.3% to ₹84 crore, showing some improvement in recent performance.

Valuation multiples

The stock trades at 20.7 times earnings, a discount to the Healthcare median of 32.0, 9.11 times book value. It yields 2.4%.

Things to watch

The company's net profit margin fell 2.8 percentage points to 17.8%, indicating pressure on profitability. The stock is 38.0% below its 52-week high, showing a significant decline from recent peak levels. Dividend payouts have become inconsistent, with a drop from ₹167 to ₹123 per share over the last two financial years.

Where it stands

Sanofi India's annual net profit fell 21.1% despite a 7.8% rise in quarterly revenue, highlighting challenges in maintaining profitability. The stock is 38.0% below its 52-week high, and recent dividend cuts raise concerns about financial stability. The most significant movement is the drop in net profit margin, which suggests ongoing pressure on margins.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.